Skip to main
IMUX
IMUX logo

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immunic Inc's pipeline, particularly the development of IMU-838, shows strong potential due to its favorable safety profile and improved treatment benefits for chronic inflammatory diseases, particularly relapsing-remitting multiple sclerosis (RMS). The Phase 2 studies have indicated that IMU-838 may offer comparable or superior efficacy compared to standard of care therapies while maintaining a low discontinuation rate, suggesting high tolerability among patients. Additionally, the dual mechanism of action encompassing both anti-inflammatory and neuroprotective properties positions IMU-838 uniquely within the competitive landscape, enhancing its prospects for successful market entry and acceptance.

Bears say

Immunic Inc has faced significant challenges with disappointing late-stage trial results, particularly with its candidates evobrutinib and tolebrutinib, which did not demonstrate superiority against the established treatment Aubagio, impacting their projected commercial viability. Additionally, the company reported a net loss of $25.6 million for the third quarter of 2025 and is under financial strain, with only $35 million in capital remaining to fund ongoing studies, raising concerns about securing further funding. The combination of mixed clinical outcomes, ongoing debates regarding the commercial opportunity of their products in a crowded market, and the need for additional capital contribute to a negative outlook for Immunic's stock.

Immunic Inc (IMUX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Immunic Inc (IMUX) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.